Gammora, an innovative therapeutic agent, represents a groundbreaking approach in the realm of HIV/AIDS treatment. Developed by Israeli biotech company Zion Medical, Gammora is a synthetic peptide derived from the HIV enzyme integrase. Its unique mechanism of action targets and destroys and eliminates infected CD4+ T cells, the primary host cells for HIV, while leaving healthy cells unharmed.

This approach contrasts with conventional antiretroviral therapy (ART), which suppresses viral replication. 

Gammora's ability to directly eradicate infected cells offers the potential for a functional cure,  without the need for lifelong medication.

Clinical trials have demonstrated Gammora's efficacy in significantly reducing viral load in HIV patients. Furthermore, its safety profile has shown promising results, with minimal adverse effects reported during trials.

The excitement surrounding Gammora stems from its potential to revolutionize HIV treatment, offering hope for millions of individuals living with the virus worldwide

 larger-scale trials are still taken..to fully assess its long-term effects and feasibility as a widespread treatment option.but as for now no side effects. Gammora represents a promising step towards a future without HIV/AIDS.

NB: Phase 1, 2a and 2b  human clinical trial of Gammora, reaffirmed results of prior preclinical trials showing the safety, tolerability and effectiveness of the drug in killing infected cells:.

 : In phase one ( 1) with single treatment of Gammora, most patients showed a significant reduction in viral load of up to 90% during the first four weeks.

: In phase two (II) of the study, patients were given Gammora in combination with a commercially available Aluvia tablets (daily). The results found that combined-treated patients showed up to 99% reduction in viral load with in four weeks.  Showing 35-45 copies in a blood sample,

 Not only did the drug reportedly lack side-effects,but it also increased the amount of CD4 cells in the patients, a sign of a healthy immune system

Then the  last phase which is 2b. study trial with the help of mixed black seed oil and the combined treatment  the patients got ...zero viral load "meaning the patients have no HIV virus 🦠 " in a period of four weeks...Gammora was licensed from the  Hebrew University of Jerusalem, infection.